1. 97P Toxicity of bispecific antibody glofitamab in patients with aggressive B-cell non-Hodgkin lymphoma in real clinical practice. (December 2022) Authors: Fedorova, L.; Smykova, O.; Chekalov, A.; Lepik, E.; Markelov, V.; Popova, M.; Kondakova, E.; Moiseev, I.; Lepik, K.; Mikhailova, N.; Kulagin, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1077: HODGKIN LYMPHOMA IN PATIENTS WITH HIV: NATIONAL RETROSPECTIVE MULTICENTER STUDY. (23rd June 2022) Authors: Chekalov, A.; Popova, M.; Tsygankov, I.; Rogacheva, Y.; Volkov, N.; Beynarovich, A.; Lepik, K.; Demchenkova, M.; Schneider, T.; Kopeikina, Y.; Potapenko, V.; Zyuzgin, I.; Kolesnikova, M.; Pospelova, T.; Zinina, E.; Myasnikov, A.; Kaplanov, K.; Ksenzova, T.; Pavlyuchenko, E.; Mikhaylova, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 967 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA. (23rd June 2022) Authors: Fedorova, L.; Lepik, K.; Mikhailova, N.; Kondakova, E.; Komarova, Y.; Popova, M.; Kotselyabina, P.; Borzenkova, E.; Baykov, V.; Moiseev, I.; Kulagin, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 970 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1724: QUALITY OF LIFE AND UNMET NEEDS AMONG PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS: RESULTS OF THE NATIONWIDE SURVEY. (23rd June 2022) Authors: Ionova, T.; Andreevskaya, E.; Babich, E.; Bulieva, N.; Vinogradova, O.; Volodicheva, E.; Voloshin, S.; Glonina, N.; Dubov, S.; Esefieva, N.; Zinina, E.; Ivanova, M.; Klitochenko, T.; Kopylova, A.; Kulagin, A.; Kuchma, G.; Li, O.; Lomaia, E.; Melikyan, A.; Melnichenko, V. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS. (23rd June 2022) Authors: Kulasekararaj, A.; Brodsky, R.; Griffin, M.; Kulagin, A.; Ogawa, M.; Wang, J.; Mujeebuddin, A.; Nishimura, J.-I.; Peffault de Latour, R.; Szer, J.; Lee, J. W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 706 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION. (23rd June 2022) Authors: Dale, D. C.; Alsina, L.; Azar, A.; Badolato, R.; Bertrand, Y.; Deya, A.; Dickerson, K. E.; Ezra, N.; Hasle, H.; Kang, H. J.; Kiani-Alikhan, S.; Kuijpers, T.; Kulagin, A.; Langguth, D.; Levin, C.; Neth, O.; Peake, J.; Rutten, C. E.; Shcherbina, A.; Tarrant, T. K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1814 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗